Literature DB >> 16905370

Differential influence of iNOS and nNOS inhibitors on rostral ventrolateral medullary mediated cardiovascular control in conscious rats.

Marli C Martins-Pinge1, Martha R L Garcia, Daniel B Zoccal, Carlos C Crestani, Phileno Pinge-Filho.   

Abstract

We evaluated the cardiovascular effects of nitric oxide (NO) inhibitors microinjected into the rostral ventrolateral medulla (RVLM) of conscious rats. Application of L-NAME or aminoguanidine (AG) induced an increase in arterial blood pressure (MAP) and an increase in heart rate, whereas 7-nitroindazole (7-NI) decreased MAP and HR. Microinjection of glutamate produced an increase in MAP which was followed by either a tachycardia or a bradycardia. Such responses were blocked totally by prior administration of L-NAME and attenuated (approximately 50%) by 7-NI. In contrast, glutamate responses were enhanced by following AG. We conclude that in conscious rats, NO has tonic effects in the RVLM and may participate in the modulation of the actions of glutamate through iNOS and nNOS pathways.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16905370     DOI: 10.1016/j.autneu.2006.07.004

Source DB:  PubMed          Journal:  Auton Neurosci        ISSN: 1566-0702            Impact factor:   3.145


  17 in total

Review 1.  Implicating the potential role of orexin in hypertension.

Authors:  Monika Rani; Raghuvansh Kumar; Pawan Krishan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-05-16       Impact factor: 3.000

2.  Enhancement of rostral ventrolateral medulla neuronal nitric-oxide synthase-nitric-oxide signaling mediates the central cannabinoid receptor 1-evoked pressor response in conscious rats.

Authors:  Badr Mostafa Ibrahim; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2012-02-24       Impact factor: 4.030

3.  Modulation of inducible nitric oxide synthase (iNOS) expression and cardiovascular responses during static exercise following iNOS antagonism within the ventrolateral medulla.

Authors:  Pasarapa Towiwat; Siripan Phattanarudee; Timothy J Maher; Ahmmed Ally
Journal:  Mol Cell Biochem       Date:  2014-09-19       Impact factor: 3.396

4.  Central GPR109A Activation Mediates Glutamate-Dependent Pressor Response in Conscious Rats.

Authors:  Samar Rezq; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2015-11-30       Impact factor: 4.030

5.  A pivotal role for enhanced brainstem Orexin receptor 1 signaling in the central cannabinoid receptor 1-mediated pressor response in conscious rats.

Authors:  Badr Mostafa Ibrahim; Abdel A Abdel-Rahman
Journal:  Brain Res       Date:  2015-06-18       Impact factor: 3.252

6.  Rostral Ventrolateral Medulla EP3 Receptor Mediates the Sympathoexcitatory and Pressor Effects of Prostaglandin E2 in Conscious Rats.

Authors:  Samar Rezq; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2016-08-29       Impact factor: 4.030

7.  Characterization of the non-adrenergic/non-cholinergic response to perivascular nerve stimulation in the double-perfused mesenteric bed of the mouse.

Authors:  E Legros; C R Tirapelli; E Carrier; I Brochu; A Fournier; P D'Orléans-Juste
Journal:  Br J Pharmacol       Date:  2007-10-01       Impact factor: 8.739

8.  Dual role of nitrergic neurotransmission in the bed nucleus of the stria terminalis in controlling cardiovascular responses to emotional stress in rats.

Authors:  Lucas Barretto-de-Souza; Mariane B Adami; Ricardo Benini; Carlos C Crestani
Journal:  Br J Pharmacol       Date:  2018-08-17       Impact factor: 8.739

9.  Activation of estrogen receptor beta-dependent nitric oxide signaling mediates the hypotensive effects of estrogen in the rostral ventrolateral medulla of anesthetized rats.

Authors:  Cheng-Dean Shih
Journal:  J Biomed Sci       Date:  2009-07-07       Impact factor: 8.410

10.  Acupuncture Attenuates Blood Pressure via Inducing the Expression of nNOS.

Authors:  Lu Wang; Na-Na Yang; Guang-Xia Shi; Li-Qiong Wang; Qian-Qian Li; Jing-Wen Yang; Cun-Zhi Liu
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-18       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.